Biogen (BIIB) PT Raised to $320 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018
July 25, 2018 10:38 AM EDTEisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimers Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. This poster presentation was accepted as a Late Breaking Abstract for AAIC (Poster No.: P4-389).
Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with... More
Biogen (BIIB) PT Raised to $392 at Morgan Stanley
July 25, 2018 7:46 AM EDTMorgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $392.00 (from $366.00) while maintaining a Overweight rating.
... MoreBiogen (BIIB) PT Raised to $357 at RBC Capital
July 25, 2018 7:44 AM EDTRBC Capital raised its price target on Biogen (NASDAQ: BIIB) to $357.00 (from $349.00) while maintaining a Sector Perform rating.
Analyst Brian Abraham said the solid quarter with guidance raise should help keep enthusiasm high for BIIB following recent de-risking of key Alzheimer's portfolio.
... MoreBiogen (BIIB) PT Raised to $348 at Baird
July 25, 2018 6:40 AM EDTBaird raised its price target on Biogen (NASDAQ: BIIB) to $348.00 (from $323.00) while maintaining a Neutral rating.
Analyst Brian Skorney commented, "Biogen reported in-line revenues of $3.4B and EPS of $5.80, beating consensus at $5.21. A return for growth for Spinraza and solid performance... More
Biogen (BIIB) PT Raised to $445 at JPMorgan
July 24, 2018 1:55 PM EDTJPMorgan raised its price target on Biogen (NASDAQ: BIIB) to $445.00 (from $400.00) while maintaining a Overweight rating.
Analyst Cory Kasimov remains positive on the company following a strong beat and raise in Q2. The analyst notes the resilience of the core portfolio and... More
Biogen (BIIB) Tops Q2 EPS by 56c, FY Guidance Tops Consensus
July 24, 2018 6:37 AM EDT(Updated - July 24, 2018 6:39 AM EDT)
Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.80, $0.56 better than the analyst estimate of $5.24. Revenue for the quarter came in at $3.36 billion versus the consensus estimate of $3.26 billion.
GUIDANCE:
Biogen sees FY EPS of $24.90-$25.50 vs... More
